Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04613479

Enrollment

Registered

2020-11-03

Start date

2020-12-01

Completion date

2022-06-01

Last updated

2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatobilliary Manifestations in Inflammatory Bowel Disease Patients

Brief summary

Hepatobilliary manifestations as extraintestinal manifestations of IBD are sometimes underdiagnosed which can impair patient prognosis

Detailed description

Non alcoholic fatty liver is aliver disease most commonly found in patient with IBD most commonly without intestinal activity. On the other hand primary according cholangitis is the most common specific with IBD commonly with ulcerative colitis. and is commonly overlap with autoimmune hepatitis IBD therapy can also be a cause it can lead to hepatic toxicity and some drugs like ant TNF can cause hepatitis b virus activation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

all patients diagnosed IBD crohns and ulcerative on conventional treatment and biological treatment -

Exclusion criteria

no \-

Design outcomes

Primary

Measure	Time frame
The prevelance of hepatobilliary manifestations in IBD patients	1 year

Contacts

Primary ContactHussein Elamin

sehshammam@gmail.com01004084187

Outcome results